solabegron Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Solabegron is a drug which acts as a selective agonist for the β3 adrenergic receptor. It is being developed for the treatment of overactive bladder and irritable bowel syndrome. It has been shown to produce visceral analgesia by releasing somatostatin from adipocytes.   Wikipedia

Chemistry

  • SMILES: O[C@@H](CNCCNc1cccc(c1)c2cccc(c2)C(=O)O)c3cccc(Cl)c3
  • InChIKey: LLDXOPKUNJTIRF-QFIPXVFZSA-N
  • Mol. Mass: 410.9
  • ALogP: 4.44
  • ChEMBL Molecule:
    solabegron  
More Chemistry

Pharmacology

Alternative names

3'-((2-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)ethyl)amino)-(1,1'-biphenyl)-3-carboxylic acid | gw427353 | gw 427353 | gw-427353 | (r)-3'-((2-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)ethyl)amino)-(1,1'-biphenyl)-3-carboxylic acid | solabegron | solabegron hydrochloride

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Irritable Bowel Syndrome (Phase 2)

Urinary Bladder, Overactive (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue